FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129342006> ?p ?o ?g. }

• W2129342006 abstract "With interest we read the article by Tsai and colleagues (Tsai et al. 2013) describing an increased risk of being diagnosed with erectile dysfunction in males with central serous chorioretinopathy (CSC). In this article, it is hypothesized that vascular obstruction due to endothelial dysfunction may be an underlying mechanism in CSC. Strikingly, an inappropriate activation of the mineralocorticoid receptor, found in the choroidal vasculature (endothelial and smooth muscle cells), has also been recently suggested to underlie the pathogenesis of CSC (Zhao et al. 2012). This study also suggested a reduction in subretinal fluid (SRF) level in two patients by systemic use of eplerenone, a selective mineralocorticoid receptor antagonist, implying that eplerenone could be a promising treatment. Here we report the treatment outcome with oral eplerenone in five patients suffering from chronic CSC, who experienced persistent SRF on spectral-domain optical coherence tomography (OCT) for at least 9 months and responded insufficiently to previous treatments. Oral administration of eplerenone 25 mg/day was started at baseline. At the start of week 2, eplerenone was increased to 50 mg/day and completely stopped at the end of week 5, according to the previously described protocol (Zhao et al. 2012). A fixed follow-up protocol was used with visits scheduled at baseline, 1, 3, 5 weeks and a final examination after 10 weeks. The five patients (three males) had a mean age of 55 years (range 41–64 years), and two patients had bilateral active chronic CSC. None of the patients had a history of steroid use. A full reduction of SRF on OCT was seen in patient 1 (Fig. 1A). In this patient, there was only a minor increase in visual acuity (VA), which is most likely the result of the prolonged detachment of the neurosensory retina, causing irreversible damage to the photoreceptors (Wang et al. 2002). Patient 2 initially had a decrease in SRF but then relapsed after cessation of the eplerenone treatment (Fig. 1B). Patient 3 showed a decrease in subfoveal SRF, but showed an increase in SRF inferior of the fovea (Fig. 1C). Patient 4 had no change in SRF, nor a clear effect on VA (Fig. 1D). Patient 5 had bilateral active disease, in which one eye first had a decrease in SRF which then returned to baseline-level, whereas an increase in SRF occurred in the other eye (Fig. 1E). The use of eplerenone did not influence the hyperfluorescent pattern, typical for chronic CSC, that was seen in all patients on fluorescein angiography and indocyanine green angiography. None of the patients showed a change in subfoveal choroidal thickness on enhanced-depth-imaging-OCT during the course of the study, and systemic parameters remained within normal range in all patients. Curative therapeutic options for chronic CSC are scarce and the current leading options consist of photodynamic therapy treatment, conventional laser treatment, or micropulse laser treatment, with anatomical success rates in photodynamic therapy treatment ranging from 60 up to 100% (Quin et al. 2013). A lack of response to these treatment modalities is not uncommon. Zhao and colleagues (Zhao et al. 2012) described that an overstimulation of the mineralocorticoid receptor in a rat model caused dilation of the choroidal vasculature and choroidal thickening, similar to clinical observations in chronic CSC. The same group recently presented promising results in 13 patients with CSC, showing a full reduction of SRF in 25% of the patients at 1 month and 67% at 3 months after use of eplerenone (Bousquet et al. 2013). However, the current pilot study indicates that eplerenone has a beneficial effect only in a minority of patients with long-standing treatment-resistant chronic CSC. The precise role of an inappropriate activation of the mineralocorticoid receptor in chronic CSC therefore remains controversial. This study was supported by the following foundations: ‘Stichting MD Fonds’, ‘Gelderse Blindenstichting’, ‘Landelijke Stichting voor Blinden en Slechtzienden’ and ‘Oogfonds’ that contributed through ‘UitZicht’ and the ‘JANIVO Stichting’. The funding organizations had no role in the design or conduct of this research. No author has any financial/conflicting interests in the products mentioned in the article." @default.
• W2129342006 created "2016-06-24" @default.
• W2129342006 creator A5046758749 @default.
• W2129342006 creator A5049656883 @default.
• W2129342006 creator A5066789689 @default.
• W2129342006 creator A5083258664 @default.
• W2129342006 creator A5086926273 @default.
• W2129342006 date "2014-04-02" @default.
• W2129342006 modified "2023-09-27" @default.
• W2129342006 title "The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy" @default.
• W2129342006 cites W1519141741 @default.
• W2129342006 cites W1959393311 @default.
• W2129342006 cites W2009658202 @default.
• W2129342006 cites W2023925443 @default.
• W2129342006 cites W2151703860 @default.
• W2129342006 doi "https://doi.org/10.1111/aos.12392" @default.
• W2129342006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24698599" @default.
• W2129342006 hasPublicationYear "2014" @default.
• W2129342006 type Work @default.
• W2129342006 sameAs 2129342006 @default.
• W2129342006 citedByCount "37" @default.
• W2129342006 countsByYear W21293420062014 @default.
• W2129342006 countsByYear W21293420062015 @default.
• W2129342006 countsByYear W21293420062016 @default.
• W2129342006 countsByYear W21293420062017 @default.
• W2129342006 countsByYear W21293420062018 @default.
• W2129342006 countsByYear W21293420062019 @default.
• W2129342006 countsByYear W21293420062020 @default.
• W2129342006 countsByYear W21293420062021 @default.
• W2129342006 countsByYear W21293420062022 @default.
• W2129342006 crossrefType "journal-article" @default.
• W2129342006 hasAuthorship W2129342006A5046758749 @default.
• W2129342006 hasAuthorship W2129342006A5049656883 @default.
• W2129342006 hasAuthorship W2129342006A5066789689 @default.
• W2129342006 hasAuthorship W2129342006A5083258664 @default.
• W2129342006 hasAuthorship W2129342006A5086926273 @default.
• W2129342006 hasBestOaLocation W21293420061 @default.
• W2129342006 hasConcept C126322002 @default.
• W2129342006 hasConcept C126894567 @default.
• W2129342006 hasConcept C150173356 @default.
• W2129342006 hasConcept C164705383 @default.
• W2129342006 hasConcept C189135053 @default.
• W2129342006 hasConcept C2776069600 @default.
• W2129342006 hasConcept C2776379505 @default.
• W2129342006 hasConcept C2778525890 @default.
• W2129342006 hasConcept C2780072264 @default.
• W2129342006 hasConcept C2780972559 @default.
• W2129342006 hasConcept C71924100 @default.
• W2129342006 hasConcept C90924648 @default.
• W2129342006 hasConceptScore W2129342006C126322002 @default.
• W2129342006 hasConceptScore W2129342006C126894567 @default.
• W2129342006 hasConceptScore W2129342006C150173356 @default.
• W2129342006 hasConceptScore W2129342006C164705383 @default.
• W2129342006 hasConceptScore W2129342006C189135053 @default.
• W2129342006 hasConceptScore W2129342006C2776069600 @default.
• W2129342006 hasConceptScore W2129342006C2776379505 @default.
• W2129342006 hasConceptScore W2129342006C2778525890 @default.
• W2129342006 hasConceptScore W2129342006C2780072264 @default.
• W2129342006 hasConceptScore W2129342006C2780972559 @default.
• W2129342006 hasConceptScore W2129342006C71924100 @default.
• W2129342006 hasConceptScore W2129342006C90924648 @default.
• W2129342006 hasFunder F4320325760 @default.
• W2129342006 hasFunder F4320326339 @default.
• W2129342006 hasFunder F4320326341 @default.
• W2129342006 hasIssue "6" @default.
• W2129342006 hasLocation W21293420061 @default.
• W2129342006 hasLocation W21293420062 @default.
• W2129342006 hasOpenAccess W2129342006 @default.
• W2129342006 hasPrimaryLocation W21293420061 @default.
• W2129342006 hasRelatedWork W2025877223 @default.
• W2129342006 hasRelatedWork W2067215379 @default.
• W2129342006 hasRelatedWork W2093131177 @default.
• W2129342006 hasRelatedWork W2105712276 @default.
• W2129342006 hasRelatedWork W2130764257 @default.
• W2129342006 hasRelatedWork W2155850078 @default.
• W2129342006 hasRelatedWork W2312942238 @default.
• W2129342006 hasRelatedWork W2320541894 @default.
• W2129342006 hasRelatedWork W2322243425 @default.
• W2129342006 hasRelatedWork W3156554212 @default.
• W2129342006 hasVolume "92" @default.
• W2129342006 isParatext "false" @default.
• W2129342006 isRetracted "false" @default.
• W2129342006 magId "2129342006" @default.
• W2129342006 workType "article" @default.